You are not currently logged in.
Access your personal account or get JSTOR access through your library or other institution:
Acellular Pertussis Vaccines Developed in Japan and Their Application for Disease Control
The Journal of Infectious Diseases
Vol. 174, Supplement 3. Caring for the Next Generation: Developments in Pediatric Vaccination (Nov., 1996), pp. S264-S269
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/30126259
Page Count: 6
Preview not available
Acellular pertussis vaccines, comprising mainly pertussis toxin and filamentous hemagglutinin (FHA) and used successfully in Japan since 1981, were evaluated. Anti-pertussis toxin antibody responses in children immunized with acellular pertussis vaccines were comparable or higher than in convalescent-stage patients with pertussis, while those for anti-FHA were far higher. Reactogenicity was much less than with whole cell pertussis vaccines: Fever 38°C occurred in 2%-4% of vaccinees; there was little redness ≥5 cm in diameter at the vaccination site with the first dose but occurred in 7%-8% of vaccinees with subsequent doses. The estimated efficacy of acellular pertussis vaccine in children ages 2-8 years was 84% (95% confidence interval, 71%-91%). Since vaccineinduced immunity weakens after 6-10 years, adults are now a major source of pertussis transmission. The source of infection was an adult in 11.2% (10/89) of cases, and the secondary attack rate was 10.3% (19/185). Immunization with acellular pertussis vaccines for both adults and children is recommended for disease control.
The Journal of Infectious Diseases © 1996 Oxford University Press